genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2016
Endocrine gland cancer
Cancer
AstraZeneca NSCLC Candidate Selumetinib Fails Phase III Trial
Drug Discovery
Ipsen Partnering with Exelixis to Develop Cabozantinib
Cancer
Neuroblastoma Deploys Energy-Draining Weapon against Immune System
Cancer
Drug-Resistant Neuroblastoma Aided by miRNA in Tumor Microenviroment
Insights
Fine-Combing the Cancer Transcriptome
Best of the Web
Endocrine Web
Cancer
Ignyta, Nerviano Ink $3.5M License Agreement for Kinase Inhibitors
Cancer
Sorafenib-Capecitabine Combination Fails Phase III Trial
Cancer
$2.437M Grant to Fund NY Genome Center Pediatric Cancer Research Effort
Cancer
Memorial Sloan-Kettering to Use Sutro Technology for Neuroblastoma Research
1
2
3
...
6
Page 2 of 6
Scroll Up
Scroll Up
